Pharma

Aura Biosciences Takes Key Steps to Advance Lead Candidate

By Rich Kirkner | March 31, 2021

With a fresh infusion of capital and a new chief operating officer steeped in regulatory affairs, Aura Biosciences has put key pieces into place to…

Read More

Biomedical Informatics Helps Focus Director Dr. Michael Chiang’s Vision for NEI

By Rich Kirkner | March 23, 2021

Michael F. Chiang, MD, who took over as director of the National Eye Institute at the close of 2020, brings a unique background as an…

Read More

New Technology and Teamwork Are Key for Combining Forces

By Steve Lenier | March 16, 2021

Science and teamwork are important factors for companies considering acquisitions, collaborations, or partnerships in the dry eye space. That was the consensus of corporate leaders…

Read More

What’s a SPAC? A Route to Public Markets for Gemini Therapeutics

By Heather Johnson | March 3, 2021

Gemini Therapeutics, a biotech company with a focus on precision medicine for ocular and renal disease, started trading last month on the Nasdaq Global Market…

Read More

Ocular Gene Therapy Takes Next Step Beyond Inherited Retinal Disease

By Rich Kirkner | February 23, 2021

Ten years from now, gene therapy for ocular disease will have made the shift from exclusively targeting inherited retinal diseases with very small populations, such…

Read More

With New Clarity of Trial Data, Outlook Therapeutics Stock Rebounds

By Heather Johnson | February 10, 2021

What a difference a few months makes. Outlook Therapeutics’ stock price plunged last August on the heels of top-line results from the NORSE 1 clinical…

Read More

Manufacturing Strategy Key to AGTC’s Next Steps for Gene Therapy Programs

By Rich Kirkner | August 18, 2020

As Applied Genetic Technologies Corp. takes the next steps in the development of its lead gene therapy candidate for inherited retinal disease, the company has…

Read More

Osmotica Will Commercialize and Supply Non-Surgical Droopy Lid Treatment via a Wholly Owned Subsidiary

By Conni Bergmann Koury | August 5, 2020

Last month, the US Food and Drug Administration approved a novel ophthalmic solution to treat acquired blepharoptosis, otherwise known as “droopy lid syndrome.” The solution,…

Read More
AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

AbbVie Regroups after FDA Issues Complete Response Letter Rejecting Abicipar Pegol

By Steve Lenier | July 9, 2020

Weeks after completing its acquisition of Allergan, AbbVie is seeking a meeting with the US Food and Drug Administration to talk about the next steps…

Read More
With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

By Conni Bergmann Koury | July 1, 2020

Oyster Point Pharma has taken two big steps recently to advance development of its OC-01 nasal-spray candidate to treat dry eye disease: the closing of…

Read More
With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

By Steve Lenier | April 29, 2020

Developing a delivery system to replace eye drops has been an important unmet need in ophthalmology. Drops are difficult or impossible for some patients to…

Read More
Adverum, Gene Therapy, and AMD

Adverum, Gene Therapy, and AMD

By Steve Lenier | March 25, 2020

Adverum, a company pioneering novel gene therapies for ocular diseases, believes a gene therapy treatment for wet age-related macular degeneration (AMD) can reduce treatment burden…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.